 "Strides Arcolab gains on USFDA nod for Lamivudine and Zidovudine tablets")
Shares of Strides Arcolab were trading higher by 4% to Rs 1,069 on the NSE after a pharmaceutical company said that it has received approval from the US health regulator for Lamivudine and Zidovudine tablets.
“The company has received approval from US Food and Drug Administration (USFDA) for Lamivudine and Zidovudine tablets in strengths of 150 and 300 mg”, Strides Arcolab said in a statement.
Lamivudine and Zidovudine tablets belong to a group of antiviral medicines, also known as antiretrovirals and used to treat Human Immunodeficiency Virus (HIV) infection.
The company said, the product will be manufactured at the company's oral dosage facility at Bangalore and marked by Strides in the US Market. The product will be launched in the markets immediately.
According to IMS data, the US market for Lamivudine and Zidovudine tablets is approximately $120 million, it added.
The stock opened at Rs 1,043 and touched high of Rs 1,077 on the NSE. A combined 485,191 shares changed hands on the counter on the NSE and BSE till 1119 hours.
“The company has received approval from US Food and Drug Administration (USFDA) for Lamivudine and Zidovudine tablets in strengths of 150 and 300 mg”, Strides Arcolab said in a statement.
Lamivudine and Zidovudine tablets belong to a group of antiviral medicines, also known as antiretrovirals and used to treat Human Immunodeficiency Virus (HIV) infection.
The company said, the product will be manufactured at the company's oral dosage facility at Bangalore and marked by Strides in the US Market. The product will be launched in the markets immediately.
According to IMS data, the US market for Lamivudine and Zidovudine tablets is approximately $120 million, it added.
The stock opened at Rs 1,043 and touched high of Rs 1,077 on the NSE. A combined 485,191 shares changed hands on the counter on the NSE and BSE till 1119 hours.